Sionna Therapeutics, Inc. Share Price & Technical Analysis
SION · $41.13 (-1.49%)
Healthcare / Biotechnology
$41.13
-1.49%
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, …
Price chart
Seasonality
May has 2 positive and 0 negative years (last 2 years shown)
6% return in May, 13% avg return in past 3 year May month.
13% return in 2026, 105% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 2% | -13% | 22% | -4% | 6% | – | – | – | – | – | – | – | 13% |
| 25 | – | -45% | -23% | 17% | 13% | 25% | -3% | 50% | 20% | 32% | 17% | 1% | 105% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.94B
P/E ratio
—
52W high
$48.45
52W low
$12.53
Volume
1,82,571
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Sionna Therapeutics, Inc. share price today?
- Sionna Therapeutics, Inc. (SION) last traded around $41.13 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SION have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SION. Download the app for real-time alerts.
- How can I analyze Sionna Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.